Table 2.

Survival based on derived AJCC stage, 6th edition for selected adnexal carcinomas

	All adnexal	Sweat gland carcinoma	Hidradenocarcinoma	Spiradenocarcinoma	Sclerosing sweat duct tumor (MAC)	Porocarcinoma	Eccrineadenocarcinoma	Sebaceous carcinoma (n, %)
Stage (derived AJCC stage group, 6th ed (2004–2015)	N = 1863	N = 70	N = 127	N = 46	N = 236	N = 229	N = 187	N = 968
I (n, %)	1221 (65.5)	40 (57.1)	56 (44.1)	14 (30.4)	150 (63.6)	140 (61.1)	103 (55.1)	718 (74.2)
II (n, %)	440 (23.6)	14 (20.0)	54 (47.5)	28 (60.9)	47 (19.9)	64 (27.9)	51 (27.3)	182 (18.8)
III (n, %)	155 (8.3)	12 (17.1)	11 (8.7)	3 (6.5)	38 (16.1)	20 (8.7)	28 (15.0)	43 (4.4)
IV (n, %)	47 (2.5)	4 (5.7)	6 (4.7)	1 (2.2)	1 (0.4)	5 (2.2)	5 (2.7)	25 (2.6)
5-Year OS based on stage
I, OS (95% CI)	79.0 (75.6–82.0)	85.7 (61.7–95.2)	91.1 (74.5–97.1)	80.3 (69.9–85.4)	87.7 (79.2–92.9)	78.4 (67.5–86.1)	80.2 (67.9–88.1)	74.1 (69.0–78.5)
II, OS (95% CI)	74.4 (68.8–79.2)	53.5 (21.2–77.7)	80.9 (63.6–90.6)	60.3 (35.3–78.2)	85.0 (67.6–93.5)	77.4 (60.9–87.6)	72.4 (55.0–85.3)	73.3 (63.7–80.7)
III, OS (95% CI)	67.4 (56.6–76.0)	62.5 (22.9–86.1)	53.3 (17.7–79.6)	–	83.3 (61.0–93.4)	52.9 (24.3–76.3)	81.4 (52.8–93.6)	53.2 (30.3–71.7)
IV, OS (95% CI)	17.1 (4.6–26.5)	–	–	–	–	–	–	30.0 (7.1–57.8)
5–Year DSS based on stage
I, DSS (95% CI)	99.3 (98.2–99.7)	100 (97.6–100)	96.5 (94.0–98.2)	97.9 (95.2–98.1)	96.9 (90.4–99.0)	97.4 (89.7–99.3)	98.7 (91.2–99.8)	99.0 (96.9–99.7)
II, DSS (95% CI)	97.8 (95.2–99.0)	87.5 (38.7–98.1)	94.1 (78.4–98.5)	90.3 (66.3–97.5)	93.3 (75.9–98.3)	95.2 (87.3–96.7)	93.9 (77.7–98.5)	98.3 (93.5–99.6)
III, DSS (95% CI)	89.0 (79.894.2)	71.4 (35.892.0)	70.0 (22.591.8)	–	83.3 (61.093.4)	66.1 (31.686.2)	–	79.8 (49.493.0)
IV, DSS (95% CI)	50.3 (18.575.7)	–	–	–	–	–	–	53.7 (13.182.7)

AJCC American Joint Committee on Cancer, OS overall survival, DSS disease-specific survival, CI confidence interval